Zobrazeno 11 - 20
of 263
pro vyhledávání: ''
Autor:
Koichi Takeda, Brian Hayama, Toshiharu Sasaki, Kenji Nakano, Daisuke Ohkushi, Kosuke Hoashi, Koh Okamoto, Taisuke Enokida, Sohei Harada
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer
BMC Cancer
Background Pneumocystis jirovecii pneumonia (PCP)-related risk factors among patients with solid tumors are not completely defined. Thus, we aimed to characterize PCP cases with underlying solid tumors, to highlight the factors contributing to its de
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Paclitaxel (Taxol) is a microtubule-stabilizing drug used to treat several solid tumors, including ovarian, breast, non-small cell lung, and pancreatic cancers. The current treatment of ovarian cancer is chemotherapy using paclitaxel in co
Autor:
Hemavathi Dhandapani, Selvaluxmy Ganeshrajah, Priya Ramanathan, Rajkumar Thangarajan, Anil Suri, Hascitha Jayakumar, Shirley Sunder Singh, Nirmala Jagadish, Abirami Seetharaman
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-14 (2021)
Background Dendritic cell (DC)-based immunotherapy is capable of activating the immune system and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. However, major limitations are the availability of autologous tumor
Autor:
Marwa M. Abu‑Serie, Marwa Eltarahony
Publikováno v:
Cancer Nanotechnology, Vol 12, Iss 1, Pp 1-17 (2021)
BackgroundDisulfiram (DS), in the presence of copper (Cu), exhibited potent broad anticancer activity. However, its clinical application is limited due to the poor solubility and stability. Hence, a novel nanocombination of DS with bacterially synthe
Autor:
Sangwook Park, Dakeun Lee, Jae Seok Roe, Jong-Ho Cha, Sang-Yeong Park, Sun Mi Hong, Sung-Min Hwang, Ho Chul Kang, Michael J. Morgan, You-Sun Kim, Hwa-Ryeon Kim, Han-Hee Park
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-20 (2021)
Molecular Cancer
Molecular Cancer
Background Necroptosis is emerging as a new target for cancer immunotherapy as it is now recognized as a form of cell death that increases tumor immunogenicity, which would be especially helpful in treating immune-desert tumors. De novo synthesis of
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
Experimental Hematology & Oncology
Experimental Hematology & Oncology
We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression. After sub
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-12 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background Recent studies have consistently shown that AFC and serum AMH are good predictors of ovarian response and have shown strong correlations. However, it is not unusual for reproductive medicine specialists to encounter discordance between the
Autor:
Liyan Wang, Yanning Li, Guangqi Li, Xiaochun Zhang, Hongxia Wang, Guangxian Xu, Yanting Zhang, Liyuan Liu, Yuankui Chu, Dan Jiang
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-12 (2021)
Cancer Cell International
Cancer Cell International
BackgroundTaking advantage of nanobodies (Nbs) in immunotherapy, we investigated the cytotoxicity of Nb-based chimeric antigen receptor T cells (Nb CAR-T) against lymphoma cells.MethodsCD19 Nb CAR-T, CD20 Nb CAR-T, and Bispecific Nb CAR-T cells were
Autor:
Yizhou Zhang, Yang Yu, Zhiyun Liang, Yu Tian, Baokang Wu, Heming Zhang, Qi Lang, Xin Zhao, Chongli Zhong, Feng Xu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-16 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Immune checkpoint molecules, also known as cosignaling molecules, are pivotal cell-surface molecules that control immune cell responses by either promoting (costimulatory molecules) or inhibiting (coinhibitory molecules) a signal. These molecules hav
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-18 (2021)
Cancer Cell International
Cancer Cell International
Background Additional epidermal growth factor receptor (EGFR) mutations confer the drug resistance to generations of EGFR targeted tyrosine kinase inhibitor (EGFR-TKI), posing a major challenge to developing effective treatment of lung adenocarcinoma